Last reviewed · How we verify
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| medical nutrition therapy + metformin | medical nutrition therapy + metformin | marketed | Combination therapy: dietary intervention + biguanide antidiabetic | AMP-activated protein kinase (AMPK) and hepatic glucose metabolism (metformin component) | Endocrinology / Diabetes | |
| Orally Colostrum | Orally Colostrum | phase 3 | Biological supplement / Immunomodulator | Immunology / Gastroenterology |
Therapeutic area mix
- Endocrinology / Diabetes · 1
- Immunology / Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes:
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes pipeline updates — RSS
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes pipeline updates — Atom
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-nacional-de-perinatologia-isidro-espinosa-de-los-reyes. Accessed 2026-05-17.